• darkblurbg

    Developing therapies

    for type 1 diabetes

  • darkblurbg

    Intralymphatic immunotherapy

    with Diamyd®

Production Scientist with GMP experience

We welcome candidates with relevant life science experience to join our team.


 Dates for financial information and other events
January 20, 2021
Quarterly Report I
Quarterly Report 1 2020/2021
March 31, 2021
Quarterly Report II
Quarterly Report 2 2020/2021
June 23, 2021
Quarterly Report III
Quarterly Report 3 2020/2021
October 6, 2021
Year-End Report
Year-End Report 2020/2021

Company Presentation

Our data support the therapeutic targeting of individuals that carry the specific HLA genes that associate with the therapeutic antigen, in this case HLA DR3-DQ2 and GAD. This paves the way for a precision medicine approach in type 1 diabetes for the diabetes vaccine Diamyd®.

Ulf Hannelius
President and CEO, Diamyd Medical AB


Diamyd Medical develops therapies for type 1 diabetes
The share is listed on Nasdaq First North Growth Market (ticker: DMYD B)

Read More

Order GAD for preclinical research